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Guanylin and uroguanylin induce natriuresis in mice lacking
guanylyl cyclase-C receptor.
Background. Guanylin (GN) and uroguanylin (UGN) are in-
testinally derived peptide hormones that are similar in structure
and activity to the diarrhea-causing Escherichia coli heat-stable
enterotoxins (STa). These secretagogues have been shown to af-
fect fluid, Na+, K+, and Cl− transport in both the intestine and
kidney, presumably by intracellular cyclic guanosine monophos-
phate (cGMP)-dependent signal transduction. However, the
in vivo consequences of GN, UGN, and STa on renal func-
tion and their mechanism of action have yet to be rigorously
tested.
Methods. We hypothesized that intravenous administration
of GN, UGN, or STa would cause an increase in natriuresis
in wild-type mice via cGMP and guanylyl cyclase-C (GC-C,
Gucy2c), the only known receptor for these peptide-hormones,
and that the peptide-induced natriuresis would be blunted in
genetically altered mice devoid of GC-C receptors (GC-C(−/−)
null).
Results. In wild-type mice using a modified renal clearance
model, GN, UGN, and STa elicited significant natriuresis, kali-
uresis, and diuresis as well as increased urinary cGMP levels in a
time- and dose-dependent fashion. Absolute and fractional uri-
nary sodium excretion levels were greatest ∼40 minutes follow-
ing a bolus infusion with pharmacologic doses of these peptides.
Unexpectedly, GC-C(−/−) null mice also responded to the GN
peptides similarly to that observed in wild-type mice. Glomeru-
lar filtration rate (GFR), blood pressure, and plasma cGMP
in the mice (wild-type or GC-C(−/−) null) did not significantly
vary between the vehicle- and peptide-treatment groups. The
effects of UGN may also influence long-term renal function
due to down-regulation of the Na+/K+ ATPase c -subunit and
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the Cl− channel ClC-K2 by 60% and 75%, respectively, as as-
sessed by differential display polymerase chain reaction (PCR)
(DD-PCR) and Northern blot analysis of kidney mRNA from
mice treated with UGN.
Conclusion. GN, UGN, and STa act on the mouse kidney, in
part, through a cGMP-dependent, GC-C–independent mecha-
nism, causing significant natriuresis by renal tubular processes.
UGN may have further long-term effects on the kidney by al-
tering the expression of such transport-associated proteins as
Na+/K+ ATPase and ClC-K2.
The kidney plays a critical role in the maintenance
of extracellular fluid volume, and as a consequence,
blood pressure, by regulating total body NaCl content
[1, 2]. Fundamentally, alterations in NaCl content (either
through changes in intake or through inappropriate ex-
trarenal loss) lead to adjustments in urinary NaCl excre-
tion that are designed to ultimately help restore normal
levels. It is well established in both humans and in exper-
imental animals that orally administered NaCl loads can
be excreted more rapidly than equivalent salt loads ad-
ministered intravenously [3–7]. These observations sup-
port a concept that NaCl intake may be monitored by
the intestine, and that an increased delivery results in the
generation of a signal to the kidney that begins to adjust
sodium excretion to match intake prior to the absorption
of sufficient NaCl to cause significant changes in extra-
cellular fluid volume [8, 9]. For example, urinary sodium
excretion is significantly elevated in the 4-hour period im-
mediately after an oral salt load in rats, rabbits, and hu-
mans [3, 4, 6, 7, 10, 11]. In sharp contrast, an intravenous
salt load of the same amount causes a much smaller in-
crease in sodium excretion over the same time period.
Thus, a putative “intestinal natriuretic factor” could link
the intestine with the kidney as a means of regulating
urinary salt excretion to match dietary salt intake.
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Studies from this and other laboratories suggest that
two low-molecular-weight peptides, guanylin (GN) and
uroguanylin (UGN), may be critical components of
this enterorenal axis [9, 12–14]. In the gastrointesti-
nal tract, GN and UGN bind to and activate guanylyl
cyclase-C (GC-C) [15], an apical membrane receptor that
has an intrinsic guanylyl cyclase catalytic domain [16].
Mechanistically, receptor activation enhances intracellu-
lar guanosine-3′,5′-cyclic monophosphate (cGMP) syn-
thesis, which in turn, stimulates intestinal electrogenic
chloride and bicarbonate secretion via the cystic fibrosis
transmembrane conductance regulator (CFTR) chloride
channel and inhibits electroneutral sodium absorption [9,
15, 17]. Although GN was initially isolated from jejunum
and UGN from urine, these peptides have been found
throughout the intestine where they are released from
specific epithelial cells into both the lumen and the sys-
temic circulation [9, 18–21]. GN and UGN are structurally
similar to the heat-stable enterotoxin (STa) peptides se-
creted by pathogenic strains of enteric bacteria[9, 22].
These toxins virtually act as superagonists of GC-C and
trigger nonphysiologic movement of electrolytes within
the intestinal lumen [23].
Recent studies from this laboratory have shown that
GN and UGN can also affect renal function. Intravenous
administration of exogenous GN and UGN induce sig-
nificant natriuresis in mice [12, 24]. In addition, studies
in the isolated perfused rat kidney have shown that both
peptides are natriuretic in a time- and dose-dependent
fashion [14, 25]. Coincident with these solute excretory
patterns, urinary cGMP excretion also increased after
peptide administration. GN, UGN, and STa have also
been shown to elevate cGMP in organ-cultured kidney
slices and proximal convoluted tubule cells in vitro [26–
29]. Consistent with these functional responses, previous
studies have reported 125I-GN [30] and 125I-ST binding
[27, 31], and GC-C mRNA expression in heteroge-
neous kidney preparations [32–34]. Employing semi-
quantitative reverse transcription-polymerase chain
reaction (RT-PCR), we assessed the distribution of renal
GN/UGN receptor mRNA in specific microdissected seg-
ments of the rat nephron [32]. These results suggest that
GN/UGN/STa may affect transport in multiple nephron
segments that are involved in renal tubular handling of
NaCl since receptor mRNA expression is relatively high
in the collecting tubules, the proximal convoluted tubule,
and the medullary thick ascending limb. Lower levels of
receptor mRNA were observed in the cortical thick as-
cending limb, distal convoluted tubes, and glomeruli.
While the mechanisms that regulate the renal effects
of GN and UGN are unclear, a role for sodium intake has
been implicated. For example, the UGN concentration in
human urine and plasma is increased during a high salt
intake [34]. Additionally, perfusion of the small intestine
[35] and colon [36] in situ with hypertonic NaCl solutions
markedly increased GN (and to a lesser degree UGN)
secretion into the lumen, while perfusion with similar os-
motic concentrations of mannitol exhibited much lower
effects [21, 37]. However, in a whole animal model of os-
motic diarrhea (using a lactose-based diet), GN and UGN
mRNA and protein expression levels were significantly
increased suggesting that these genes are responsive to
the increased intraluminal hypertonicity inherent to the
model [21]. Furthermore, using HT29-18-N2 colonic cells,
hypertonic solutions (of NaCl, lactose, or mannitol) were
found to significantly increase GN and UGN expression
and secretion from the apical and basolateral surfaces of
the cell [18]. Conversely, low NaCl intake down-regulates
GN mRNA and peptide expression in the distal colon
[38]. Recent studies from this laboratory have further ex-
amined the effects of altered NaCl intake on GN and
UGN mRNA expression in the four principal regions
of the rat intestine—duodenum, jejunum, ileum, and the
colon—and have shown that both peptides are affected
by salt diet in the rat intestine [39]. More important, ex-
pression patterns could be affected within 4 hours of an
intragastric administration of NaCl, suggesting that a pu-
tative signaling system can respond rapidly to altered
NaCl intake.
Although these data are compelling and support a hy-
pothesis that the renal effects of intestinally derived GN
and UGN are involved in the maintenance of salt and wa-
ter homeostasis, no detailed analysis of the renal action
and mechanism of natriuresis by these peptides have been
rigorously evaluated. Therefore, the principal aim of the
present study was to elucidate the renal effects and the
mechanism(s) of GN and UGN action in vivo employing a
modified mouse clearance model. In addition, to address
the renal mechanism by which these peptides elicit natri-
uresis, we evaluated how this system acts in GC-C(−/−)
null (Gucy2c −/−) mice. Here, we show that intravenous
administration of GN and UGN increase absolute and
fractional sodium excretion in wild-type and GC-C(−/−)
null mice in a rapid, time- and dose-dependent fashion. It
has been assumed that the renal effects of GN/UGN are
mediated by peptide binding to GC-C [9, 32, 40]. How-
ever, data in this report would suggest the presence of
an alternate renal GN/UGN/STa receptor. Therefore, a
second goal of the present study was to begin to address,
using a molecular approach, the presence of this GC-C
independent mechanism of renal GN/UGN action.
EXPERIMENTAL PROCEDURES
Mouse models
Mice lacking the GC-C receptor were generated as pre-
viously described [41]. Embryonic stem cells (E14TG2A
from strain 129/Sv), selected for a targeted deletion
of Exon 1 of Gucy2c, the gene encoding GC-C, were
microinjected into Black Swiss blastocysts. Germline
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chimeric offspring were identified and bred with Black
Swiss mice. The resulting heterozygous littermates (hy-
brids of 129/Sv and Black Swiss) were bred to produce ho-
mozygous Gucy2c−/− (GC-C(−/−) null) and Gucy2c+/+
(wild-type) mice. The GC-C(−/−) null and wild-type mice
used in these experiments are the progeny of these
F2 mice. In addition, NIH Institute of Cancer Re-
search/Harlan Sprague-Dawley (ICR-HSD) mice were
also used as wild-type controls.
Suckling mouse intestinal fluid assay
In order to assess the potency and bioactivity of GN,
UGN, and STa, the peptides were tested for their ability to
induce intestinal fluid accumulation in newborn mice, as
described previously [12, 42]. ICR-HSD suckling mice, 2
to 4 days old (2.1 ± 1.0 g), were dosed orally with 0.1 mL of
test solution. The injections contained vehicle (1 mmol/L
HEPES and 0.1% Evans blue dye) alone or the peptides
dissolved in vehicle (except that GN injections contained
the protease inhibitors chymostatin (0.1 mmol) and apro-
tinin (0.67 U) [24, 25]). After administration of vehicle or
peptide agonists, the mice were kept at room tempera-
ture for 3 hours. The mice were then killed, intestinal
and body weights measured, and a ratio of the intestinal
weight to remaining body weight was calculated. A ratio
of 0.0875 represents one mouse unit of activity, indicating
significant fluid accumulation in the intestine. The secre-
tion activity (one unit) of GN (containing aprotinin and
chymostatin) was 142.9 ± 5.3 ng/mouse; UGN was 41.5 ±
1.7 ng/mouse; and for STa, 3.75 ± 0.2 ng/mouse.
Stability of GN, UGN, and STa in mouse serum
Approximately 4 units of peptide activity (GN, 550 ng;
UGN, 150 ng; STa, 15 ng) were incubated in 100 lL of
mouse serum for 120 minutes at 37◦C under 5% CO2.
Samples were mixed with an equal volume of vehicle
(1 mmol/L HEPES and 0.1% Evans blue dye) and ad-
ministered to suckling mice. The fluid accumulation in the
intestine was assessed for each peptide-containing sam-
ple containing the mouse serum or vehicle alone (con-
trol). The mean ± SEM from four to five mice/group was
used in determining representative fluid accumulation
and compared against that of the control group (peptide-
induced group without serum). Mouse plasma alone did
not significantly increase the fluid volume in the suckling
mouse intestine.
In vitro cGMP accumulation assay
The bioactivity of each peptide cGMP agonist (GN,
UGN, and STa) was tested in an in vitro tissue culture-
based cGMP accumulation assay as previously de-
scribed using T84 cells [43–45]. Briefly, T84 cells, grown
as monolayers in 24-well plates, were washed twice
with 1 mL serum-free Dulbecco’s modified Eagle’s
medium (DMEM)-F12 media (Gibco-Life Technologies,
Gaithersburg, MD, USA). The sample (0.2 mL) was
layered onto the cells and incubated for 40 minutes
at 37◦C. The media were removed, and the cells were
washed twice with serum-free media. Cells were lysed
and peptide-induced cGMP was measured using a spe-
cific nonradioactive enzyme-linked immunosorbent as-
say (ELISA) (Amersham-Pharmacia, Piscataway, NJ,
USA), and protein was measured (Bio-Rad, Hercules,
CA, USA) using bovine serum albumin (BSA) as stan-
dard. The bioactivity, which is represented as pmol cGMP
produced/min/mL, was a direct measure of the amount
of GC-C stimulating peptide present in a particular
sample. Sensitivity for this bioassay approaches 1 pmol
cGMP/well/mg protein, which is similar to the sensitivity
found previously [43, 44].
Mouse clearance-renal function assay
Six-week old male ICR/HSD mice (Harlan) (colony
bred), weighing 21.5 ± 0.7 g, were used in a modified
mouse clearance model where the bladder was catheter-
ized and/or the urethra sealed prior to vehicle or pep-
tide administration [12, 24]. Each mouse was exposed
to methoxyflurane in a desicator or 5% halothane in O2
using a mouse ventilation system until the mouse was un-
conscious (approximately 1 to 3 minutes). At this time,
the abdominal region was shaved and a 25-gauge nee-
dle was inserted through the skin to the visible bladder.
Urine was aspirated (and saved) and the bladder emp-
tied. The urethra was then cannulated by polyethylene
(PE-10) tubing and/or sealed shut with surgical glue
(Vet Bond (methyl 2-cyanoacrylate) (Midwest Veteri-
nary Supply; Madison, WI, USA) and the mouse was
placed in a restrainer to limit excessive movement. Fifty
microliters of test solution [0.1% Evans blue dye in iso-
tonic saline (vehicle) with or without peptide agonist] was
injected into the tail vein. A subset of mice, which did not
receive a tail vein injection, was also included for timed
controls. After the indicated time (0 to 120 minutes), the
animal was again exposed to methoxyflurane, the blad-
der contents emptied, and the urine volume recorded.
A mouse was used for each time point (e.g., 20, 40, 60,
80, and 120 minutes) (N = 6–8 mice per time point).
The mouse was sacrificed by open chest pneumothorax
at which point a blood sample was drawn and the kidneys
were removed for nephron segment isolation and/or renal
zone RNA isolation. The distal colon was also re-
moved for RNA isolation. In a separate set of exper-
iments, the blood pressure and heart rate were also
measured. Urine and plasma sodium, potassium, cGMP,
cyclic adenosine monophosphate (cAMP), creatinine,
and osmolality were measured. Sodium and potassium
were determined by flame photometry (Instrumenta-
tion Laboratory Autocal Flame Photometer Model 643,
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Lexington, MA, USA) and osmolality was measured by
an osmometer (Wescor 5100B Vapor Pressure Osmome-
ter, Logan, UT, USA). cGMP and cAMP were measured
by nonradioactive ELISA (Amersham-Pharmacia). Uri-
nary and plasma creatinine was measured by a spec-
trophotometric assay (Sigma Chemical Co., St. Louis,
MO, USA). Glomerular filtration rate (GFR) was de-
termined as creatinine clearance. The mice were not al-
lowed to eat 24 hours prior to the experiment, although
they were allowed to drink ad libitum. Their diet had
consisted of 18% crude protein, 9% crude fat, 4% crude
fiber, and 11% crude moisture containing 0.6% NaCl
(final net Na+ concentration of 0.2%) (Prolab Rat,
Mouse, Hamster 2000).
Messenger RNA differential display PCR
Differential display was performed on 100 ng of nor-
malized DNase-treated whole kidney RNA as described
previously [12]. Specific amplified products that showed
a difference in the display pattern between the UGN-
treated and timed vehicle-treated control mice were se-
lected for subcloning. Luminescent paint dots were used
to align the autoradiogram and gel, and only the single
most intense center band of a multiple band series was ex-
cised from the dried gel. This excised band with attached
Whatman paper was rehydrated in 100 lL of water and
eluted at room temperature for 10 minutes followed by
100◦C for 15 minutes. After cooling, the paper and gel
pieces were removed and DNA was precipitated, washed
in ethanol, and resuspended in H2O. The band was ampli-
fied by PCR again, and an aliquot was analyzed on a 1.5%
agarose gel to confirm amplification of the cDNA band of
interest. The product was ligated into the pSTBlue-1 mul-
tipurpose cloning vector for sequencing, which was per-
formed by the University of Kentucky Sequencing Core
Facility.
RNA extraction and Northern blot analysis
Total RNA was extracted from whole kidney, renal cor-
tex, and colon with Trizol. The concentration and purity
of the isolated RNA was assessed by ultraviolet spec-
trophotometry. For generation of the molecular probe,
total RNA (0.1 lg) from the renal cortex from GC-
C(−/−) null mice was treated with RNase-free DNase
to remove genomic DNA, and was subjected to reverse
transcription(RT)-PCR using thermal cycling conditions
and primers as described previously [32]. Primers for
PCR directed against mouse intestinal/renal GC-C were
selected to cross an intron-exon junction [32, 40, 41]. The
target band of expected size (∼400 bp) was gel-isolated,
followed by subcloning into the pSTBlue-1 multipurpose
cloning vector (Novagen, EMD Biosciences, San Diego,
CA, USA). Sequencing was performed by the Univer-
sity of Kentucky Sequencing Core Facility. The 400 bp
product obtained from the GC-C(−/−) null mouse kid-
ney cortex was 89% similar to the extracellular region of
mouse intestinal GC-C.
Approximately 25 lg of total RNA extracted from
colonic cells lining the intestinal lumen and kidney cortex
was run on a denaturing 1.2% agarose formaldehyde gel
(2.2 mol/L formaldehyde) and transferred to a positively-
charged nylon membrane (ICN, Costa Mesa, CA, USA)
for Northern analysis. Labeled probes (which include
murine cDNA fragments from the extracellular do-
main of GC-C [40, 41], Na+/K+-ATPase c -subunit [46],
and ClC-K2 chloride channel[47]) were used during hy-
bridization employing ExpressHyb solution (Clontech,
Palo Alto, CA, USA) following manufacturers’ protocol.
Membranes were washed two times with 2 × standard
sodium citrate (SSC)/1% sodium dodecyl sulfate (SDS)
solution (SSC = 150 mmol/L NaCl, 15 mmol/L sodium
citrate, pH 7.0) at 68◦C followed by two washes with
0.1 × SSC/0.05% SDS at 68◦C. One final membrane wash
of 2 × SSC was performed at room temperature prior
to autoradiography and phosphoimaging. Equal loading
of RNA was shown by subsequent hybridization with
b-actin. For visual purposes, blots were developed fol-
lowing 3, 7, and 14 days exposure to film.
Statistical analysis
Results are presented as the mean ± standard error
of the mean (SEM). The number (N) for each experi-
ment indicates the number of animals used in each ex-
periment or data point. Using the Student paired t test,
we assessed the statistical significance of the data with
each effect compared to its own timed control. Specific
differences between groups and time points were also de-
termined by one-way analysis of variance (ANOVA) for
unpaired groups with post hoc Newman-Keuls multiple
range test or paired ANOVA with post hoc Tukey test.
Significance was taken as P < 0.05.
RESULTS
In vitro stability studies of GN, UGN, and STa
Peptide stability studies were performed prior to per-
forming clearance experiments to determine the stability
of GN, UGN, and STa in mouse serum. Previously, we
have shown in both the suckling mouse and the isolated
perfused rat kidney that the three-dimensional struc-
ture and multiple disulfide bonds of UGN and STa pro-
vide protection from enzymatic degradation under both
in vivo and in vitro conditions [14, 24, 25, 48]. How-
ever, GN possesses a chymotrypsin-sensitive bond within
its primary 15 amino acid structure [9]. Studies with
chymotrypsin inhibitors with GN confer protection and
increase the activity of this peptide in vivo [24, 25]. There-
fore, the present study tested and compared the stability
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Table 1. Guanylin-induced changes in renal function in mice
Time minutes
Dose lg/kg
Guanylin body weight 20 40 60 80 120
Urinary flow lL/min
Vehiclea,b 0.00 2.93 ± 0.29 2.31 ± 0.20 1.73 ± 0.29 1.62 ± 0.14 1.41 ± 0.23
1 unit 6.8 ± 0.1 4.05 ± 0.63 4.35 ± 0.75c 1.98 ± 0.34 1.64 ± 0.21 1.47 ± 0.12
3 units 19.6 ± 0.2 4.96 ± 0.65c 5.01 ± 0.10c 2.78 ± 0.33c 2.18 ± 0.12 2.08 ± 0.26
10 units 64.4 ± 0.6 6.40 ± 0.89c 6.60 ± 0.61c 4.47 ± 0.55c 3.41 ± 0.32c 2.42 ± 0.33c
30 units 195.4 ± 2.7 4.55 ± 1.00c 4.28 ± 0.35c 3.94 ± 0.25c 3.05 ± 0.74c 2.35 ± 0.11c
Glomerular filtration rate lL/min
Vehicle 0.00 175.6 ± 65.4 170.7 ± 79.5 164.1 ± 36.3 156.9 ± 46.7 141.1 ± 62.1
1 unit 6.8 ± 0.1 185.4 ± 45.5 172.3 ± 63.9 160.5 ± 59.4 155.4 ± 41.0 149.1 ± 55.5
3 units 19.6 ± 0.2 176.9 ± 42.0 165.2 ± 45.9 155.4 ± 49.5 145.8 ± 39.4 138.6 ± 48.7
10 units 64.4 ± 0.6 170.5 ± 51.7 155.8 ± 53.6 142.8 ± 43.8 132.5 ± 29.7 120.6 ± 37.8
30 units 195.4 ± 2.7 161.4 ± 55.3 149.1 ± 39.7 136.1 ± 56.1 125.1 ± 33.3 121.5 ± 30.4
UNaV lEq/min
Vehicle 0.00 0.475 ± 0.121 0.403 ± 0.073 0.354 ± 0.065 0.319 ± 0.136 0.254 ± 0.119
1 unit 6.8 ± 0.1 0.675 ± 0.141 0.710 ± 0.107 0.570 ± 0.104 0.385 ± 0.078 0.263 ± 0.046
3 units 19.6 ± 0.2 1.017 ± 0.118c 0.812 ± 0.100c 0.610 ± 0.064c 0.446 ± 0.034 0.366 ± 0.080
10 units 64.4 ± 0.6 1.397 ± 0.117c 1.035 ± 0.094c 0.880 ± 0.087c 0.595 ± 0.029c 0.363 ± 0.040
30 units 195.4 ± 2.7 1.113 ± 0.171c 0.951 ± 0.106c 0.900 ± 0.077c 0.719 ± 0.113c 0.457 ± 0.035c
UKV lEq/min
Vehicle 0.00 0.268 ± 0.073 0.249 ± 0.020 0.238 ± 0.034 0.212 ± 0.027 0.172 ± 0.029
1 unit 6.8 ± 0.1 0.368 ± 0.155 0.303 ± 0.066 0.298 ± 0.024 0.254 ± 0.043 0.176 ± 0.018
3 units 19.6 ± 0.2 0.500 ± 0.094c 0.458 ± 0.049c 0.468 ± 0.089c 0.293 ± 0.082c 0.209 ± 0.044
10 units 64.4 ± 0.6 0.609 ± 0.133c 0.564 ± 0.112c 0.705 ± 0.200c 0.473 ± 0.141c 0.245 ± 0.022c
30 units 195.4 ± 2.7 0.731 ± 0.162c 0.725 ± 0.134c 0.690 ± 0.125c 0.524 ± 0.118c 0.288 ± 0.031c
Osmolality mOsm/kg
Vehicle 0.00 963.8 ± 128.3 991.1 ± 61.2 1012.6 ± 74.2 1081.7 ± 54.4 1093.8 ± 72.7
1 unit 6.8 ± 0.1 1237.0 ± 98.5 972.5 ± 85.5 1070.3 ± 134.7 1072.0 ± 95.5 871.0 ± 119.9
3 units 19.6 ± 0.2 836.8 ± 73.8 976.5 ± 60.2 1178.4 ± 113.3 1076.0 ± 80.2 933.8 ± 32.7
10 units 64.4 ± 0.6 919.1 ± 69.4 1184.3 ± 85.6 1188.3 ± 260.0 1084.2 ± 115.6 1155.9 ± 127.3
30 units 195.4 ± 2.7 1311.4 ± 152.6 1280.9 ± 116.9 945.2 ± 160.6 1320.3 ± 126.5 1353.8 ± 153.6
Abbreviations are: UNaV, sodium excretion; UKV, potassium excretion.
aTimed vehicle-controls represent the value obtained from mice treated (intravenous bolus) simultaneously with an equal volume of vehicle without peptide. Baseline
controls (preinjected control values) were obtained from a 30 lL aliquot of blood and the urine (from the bladder) 30 minutes prior to the intravenous administration
of vehicle or peptide. Plasma and urinary sodium, potassium, osmolality, and creatinine were obtained prior to and after each time point from the timed vehicle-control
and peptide-treated mice. Baseline controls were: urinary flow, 1.89 ± 0.16 lL/min; glomerular filtration rate, 188.1 ± 50.3 lL/min; UNaV, 0.694 ± 0.099 lEq/min;
UKV, 0.223 ± 0.043 lEq/min; osmolality, 950.1 ± 60.3 mOsm/kg.
bValues are means ± standard error of the mean (N = 6-8 mice/group).
cP ≤ 0.05 compared to the respective timed-vehicle control group.
of GN (in the presence of chymotrypsin inhibitors), UGN,
and STa in mouse serum. Known amounts of each bioac-
tive peptide (which were previously assessed by the suck-
ling mouse assay) were added to 100 lL of mouse serum in
a culture tube and incubated at 37◦C at pH 7.4 under 5%
CO2 atmosphere for 120 minutes. Following incubation,
50 lL of the test samples were combined with an equal
volume of vehicle and administered to suckling mice. GN,
UGN, and STa all retained >95% activity over 2 hours in
mouse serum.
Intravenous administration of GN, UGN, and STa in mice
To address the question whether GN and UGN sig-
nificantly affect renal function in vivo, experiments were
designed to measure the urine output, sodium and potas-
sium excretion, urinary cyclic nucleotide levels, and urine
osmolality after intravenous injections of the agonist-
peptides. Employing the modified mouse renal clearance
assay developed in this laboratory [12, 24], we demon-
strated that both GN and UGN cause an increase in urine
volume and total urinary sodium and potassium excretion
in a time- and dose-dependent fashion when compared to
timed-vehicle control-injected mice (Tables 1 and 2). The
urine osmolalities did not significantly vary between the
control and treated groups nor were they significantly al-
tered with respect to the time of assay (0 to 120 minutes)
or dose of peptide (0 to 30 units). The most profound
increase in absolute urinary sodium and potassium ex-
cretion was observed within 40 minutes after intravenous
peptide injection, regardless of the dose of GN or UGN
administered to the mice. The level of natriuresis by GN
and UGN appear to decrease gradually after 40 minutes
following peptide injection. For example, 40 minutes
postinjection of 30 units of GN in mice increased the
sodium excretion (UNaV) by 2.36-fold over the timed-
vehicle controls (0.403 ± 0.073 to 0.951 ± 0.106 lEq/min)
and UGN (30 units, 40-min post-injection) increased
sodium excretion by 4.20-fold (0.403 ± 0.073 to 1.694 ±
0.231 lEq/min). After 120 min, GN (30 units) increased
the sodium excretion by only 1.80-fold over the timed-
vehicle controls (0.254 ± 0.119 lEq/min to 0.457 ± 0.035
lEq/min) and UGN (30 units, 120 minutes postinjection)
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Table 2. Uroguanylin-induced changes in renal function in mice
Time minutes
Dose lg/kg
Uroguanylin body weight 20 40 60 80 120
Urinary flow lL/min
Vehiclea,b 0.00 2.93 ± 0.29 2.31 ± 0.20 1.73 ± 0.29 1.62 ± 0.14 1.41 ± 0.23
1 unit 1.9 ± 0.1 3.35 ± 0.35 3.45 ± 0.30 2.71 ± 0.37 2.43 ± 0.25 2.03 ± 0.32
3 units 5.6 ± 0.1 3.71 ± 0.64 3.81 ± 0.35 3.02 ± 0.31c 2.63 ± 0.15c 2.57 ± 0.38c
10 units 18.8 ± 0.3 5.50 ± 0.33c 5.80 ± 0.95c 3.58 ± 0.35c 3.09 ± 0.11c 2.98 ± 0.20c
30 units 56.3 ± 0.7 8.69 ± 1.21c 8.80 ± 0.97c 4.81 ± 0.33c 4.33 ± 0.73c 2.90 ± 0.27c
Glomerular filtration rate lL/min
Vehicle 0.00 175.6 ± 65.4 170.7 ± 79.5 164.1 ± 36.3 156.9 ± 46.7 141.1 ± 62.1
1 unit 1.9 ± 0.1 181.2 ± 33.9 172.5 ± 59.7 170.2 ± 47.9 149.8 ± 20.1 140.5 ± 23.3
3 units 5.6 ± 0.1 170.5 ± 30.0 164.8 ± 42.6 150.1 ± 28.4 135.2 ± 24.6 131.7 ± 42.0
10 units 18.8 ± 0.3 169.3 ± 26.3 158.5 ± 31.4 135.4 ± 27.9 125.5 ± 28.5 110.1 ± 19.8
30 units 56.3 ± 0.7 159.1 ± 30.1 147.8 ± 25.3 122.4 ± 20.7 120.7 ± 22.2 109.8 ± 16.7
UNaV lEq/min
Vehicle 0.00 0.475 ± 0.121 0.403 ± 0.073 0.354 ± 0.065 0.319 ± 0.136 0.254 ± 0.119
1 unit 1.9 ± 0.1 1.176 ± 0.127c 0.809 ± 0.091c 0.640 ± 0.103c 0.482 ± 0.044 0.287 ± 0.039
3 units 5.6 ± 0.1 1.308 ± 0.145c 0.959 ± 0.078c 0.779 ± 0.069c 0.611 ± 0.085c 0.490 ± 0.042c
10 units 18.8 ± 0.3 1.684 ± 0.248c 1.421 ± 0.116c 1.112 ± 0.109c 0.841 ± 0.056c 0.637 ± 0.039c
30 units 56.3 ± 0.7 2.097 ± 0.359c 1.694 ± 0.231c 1.491 ± 0.070c 0.859 ± 0.128c 0.587 ± 0.079c
UKV lEq/min
Vehicle 0.00 0.268 ± 0.073 0.249 ± 0.020 0.238 ± 0.034 0.212 ± 0.027 0.172 ± 0.029
1 unit 1.9 ± 0.1 0.505 ± 0.063c 0.421 ± 0.039 0.322 ± 0.046 0.224 ± 0.033 0.233 ± 0.038
3 units 5.6 ± 0.1 0.597 ± 0.104c 0.598 ± 0.081c 0.425 ± 0.075c 0.258 ± 0.040 0.253 ± 0.039
10 units 18.8 ± 0.3 0.683 ± 0.116c 0.610 ± 0.096c 0.390 ± 0.025c 0.324 ± 0.051c 0.289 ± 0.023c
30 units 56.3 ± 0.7 0.718 ± 0.097c 0.617 ± 0.067c 0.394 ± 0.049c 0.297 ± 0.041c 0.238 ± 0.007c
Osmolality mOsm/kg
Vehicle 0.00 963.8 ± 128.3 991.1 ± 61.2 1012.6 ± 74.2 1081.7 ± 54.4 1093.8 ± 72.7
1 unit 1.9 ± 0.1 1060.5 ± 115.0 935.4 ± 58.6 879.5 ± 30.4 869.8 ± 154.7 916.5 ± 123.6
3 units 5.6 ± 0.1 1222.3 ± 191.8 1014.1 ± 76.9 1056.3 ± 154.2 1002.8 ± 184.3 822.2 ± 73.3
10 units 18.8 ± 0.3 1249.7 ± 199.5 1052.3 ± 55.5 1204.7 ± 129.0 1212.6 ± 127.4 902.2 ± 56.1
30 units 56.3 ± 0.7 886.4 ± 44.0 934.6 ± 52.2 1022.2 ± 159.7 876.7 ± 71.6 1093.2 ± 82.0
Abbreviation are: UNaV, sodium excretion; UKV, potassium excretion.
aTimed vehicle- and baseline- (preinjected) control values were determined as described in Table 1. Plasma and urinary sodium, potassium, osmolality, and creatinine
were obtained prior to and after each time point (0, 20, 40, 60, 80, and 120 minutes) from the timed vehicle-control and peptide-treated groups. Baseline (preinjected)
controls were: urinary flow, 1.89 ± 0.16 lL/min; glomerular filtration rate, 188.1 ± 50.3 lL/min; UNaV, 0.694 ± 0.099 lEq/min; UKV, 0.223 ± 0.043 lEq/min; osmolality,
950.1 ± 60.3 mOsm/kg.
bValues are means ± standard error of the mean (N = 6-8 mice/group).
cP ≤ 0.05 compared to the respective timed-vehicle control group.
increased by only 2.31-fold (0.254 ± 0.119 lEq/min to
0.587 ± 0.079 lEq/min). Thus, the natriuretic effects of
GN and UGN are transient in vivo.
UGN induced greater sodium excretion than GN at
each time point of the assay. However, increased rate of
potassium excretion (UKV) was similar for both peptides.
As shown in Table 3, STa elicited a greater natriuresis than
GN or UGN; potassium excretion by STa was similar to
that of GN and UGN. Although sodium and potassium
excretion increased following GN, UGN, and STa admin-
istration, GFR decreased in a time-dependent fashion
(P > 0.05). This trend suggests the contribution of a tubu-
lar, rather than a hemodynamic, mechanism for sodium
excretion by the peptides. Plasma levels of the cyclic nu-
cleotides cGMP and cAMP were also not significantly
affected by peptide administration.
Exogenous intravenous administration of GN, UGN,
or STa in mice significantly increased fractional sodium
excretion (FENa) and urinary cGMP (FEcGMP) (Fig. 1).
Fractional excretion of sodium and potassium by GN,
UGN, and STa significantly increased as a function of
time compared to the timed-vehicle control mice. Maxi-
mal fractional sodium excretion was observed at approx-
imately 40 minutes postinjection while fractional sodium
excretion decreased toward the endpoint of the assay
(120 minutes). Elevated urinary cGMP levels are coin-
cident with the increased peptide-induced sodium excre-
tion (Fig. 1, inset). Indeed, all three peptides caused an
elevation of fractional cGMP excretion compared to con-
trol mice.
Neither blood pressure nor heart rate were affected by
intravenous peptide administration in the mice. For ex-
ample, the mean blood pressure in control mice (prein-
jection vs. vehicle-treated) after 60 minutes was 84.9 ±
10.8 mm Hg and 87.5 ± 12.8 mm Hg (N = 3), respectively,
and the heart rate slightly increased from 353 ± 15 bpm to
408 ± 42 bpm (N= 3, P > 0.05). With a 10 unit (18.8 lg/
kg body weight) UGN bolus injection, the mean blood
pressure after 60 minutes was (preinjection vs. peptide-
treated) 85.1 ± 3.3 mm Hg and 90.7 ± 3.2 mm Hg (N=
4), respectively, and the heart rate increased from 418 ±
19 bpm to 465 ± 20 bpm (N = 4, P > 0.05). Intravenous
administration of GN and STa also showed no significant
changes in heart rate or mean blood pressure.
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Table 3. Heat-stable enterotoxins (STa)-induced changes in renal function in mice
Time minutes
Dose lg/kg
STa body weight 20 40 60 80 120
Urinary flow lL/min
Vehiclea,b 0.00 2.93 ± 0.29 2.31 ± 0.20 1.73 ± 0.29 1.62 ± 0.14 1.41 ± 0.23
1 unit 0.18 ± 0.01 3.13 ± 0.24 3.20 ± 0.26c 2.58 ± 0.08c 2.42 ± 0.11c 1.61 ± 0.21
3 units 0.54 ± 0.01 5.25 ± 0.60c 5.31 ± 0.38c 3.45 ± 0.47c 3.35 ± 0.17c 1.87 ± 0.14
10 units 1.72 ± 0.03 6.45 ± 0.45c 6.62 ± 0.58c 3.82 ± 0.60c 3.86 ± 0.31c 2.01 ± 0.19
30 units 5.24 ± 0.08 7.50 ± 0.81c 7.60 ± 0.77c 3.98 ± 0.55c 3.62 ± 0.28c 2.11 ± 0.22c
Glomerular filtration rate lL/min
Vehicle 0.00 175.6 ± 65.4 170.7 ± 79.5 164.1 ± 36.3 156.9 ± 46.7 141.1 ± 62.1
1 unit 0.18 ± 0.01 176.2 ± 52.8 169.4 ± 71.3 165.2 ± 69.1 149.5 ± 54.8 138.5 ± 51.8
3 units 0.54 ± 0.01 177.8 ± 61.0 158.7 ± 55.7 139.8 ± 48.3 133.1 ± 35.6 132.4 ± 57.2
10 units 1.72 ± 0.03 164.3 ± 48.2 147.4 ± 54.9 129.5 ± 42.9 125.5 ± 29.7 121.8 ± 30.1
30 units 5.24 ± 0.08 161.2 ± 40.7 139.9 ± 33.5 121.3 ± 36.6 111.5 ± 21.4 110.8 ± 28.4
UNaV lEq/min
Vehicle 0.00 0.475 ± 0.121 0.403 ± 0.073 0.354 ± 0.065 0.319 ± 0.136 0.254 ± 0.119
1 unit 0.18 ± 0.01 0.620 ± 0.080 0.540 ± 0.036 0.481 ± 0.042 0.419 ± 0.032 0.292 ± 0.025
3 units 0.54 ± 0.01 1.135 ± 0.260c 1.002 ± 0.128c 0.890 ± 0.116c 0.773 ± 0.065c 0.382 ± 0.049
10 units 1.72 ± 0.03 1.402 ± 0.333c 1.212 ± 0.140c 1.059 ± 0.289c 0.885 ± 0.101c 0.489 ± 0.093
30 units 5.24 ± 0.08 1.734 ± 0.409c 1.510 ± 0.410c 1.349 ± 0.145c 1.010 ± 0.042c 0.553 ± 0.087c
UKV lEq/min
Vehicle 0.00 0.268 ± 0.073 0.249 ± 0.020 0.238 ± 0.034 0.212 ± 0.027 0.172 ± 0.029
1 unit 0.18 ± 0.01 0.392 ± 0.068 0.351 ± 0.036 0.299 ± 0.035 0.288 ± 0.055 0.182 ± 0.027
3 units 0.54 ± 0.01 0.456 ± 0.057c 0.401 ± 0.049c 0.341 ± 0.121 0.310 ± 0.058 0.208 ± 0.040
10 units 1.72 ± 0.03 0.616 ± 0.161c 0.511 ± 0.075c 0.397 ± 0.061c 0.312 ± 0.072c 0.232 ± 0.025c
30 units 5.24 ± 0.08 0.703 ± 0.136c 0.586 ± 0.110c 0.412 ± 0.096c 0.326 ± 0.070c 0.195 ± 0.032
Osmolality mOsm/kg
Vehicle 0.00 963.8 ± 128.3 991.1 ± 61.2 1012.6 ± 74.2 1081.7 ± 54.4 1093.8 ± 72.7
1 unit 0.18 ± 0.01 1254.3 ± 100.8 1243.3 ± 71.1 1303.3 ± 87.9 1099.1 ± 95.6 1074.0 ± 31.1
3 units 0.54 ± 0.01 853.9 ± 115.4 1083.2 ± 83.3 996.6 ± 75.3 955.8 ± 68.6 1258.5 ± 178.3
10 units 1.72 ± 0.03 1200.2 ± 119.2 997.8 ± 62.9 1023.1 ± 110.8 1043.4 ± 117.2 920.2 ± 116.2
30 units 5.24 ± 0.08 258.4 ± 99.2 1156.4 ± 62.5 931.8 ± 73.7 1291.3 ± 81.7 1019.1 ± 101.6
Abbreviations are: UNaV, sodium excretion; UKV, potassium excretion.
aTimed vehicle- and baseline- (preinjected) control values were determined as described in Table 1. Plasma and urinary sodium, potassium, osmolality, and creatinine
were obtained prior to and after each time point (0, 20, 40, 60, 80, and 120 minutes) from the timed vehicle-control and peptide-treated groups. Baseline (preinjected)
controls were: urinary flow, 1.89 ± 0.16 lL/min; glomerular filtration rate, 188.1 ± 50.3 lL/min; UNaV, 0.694 ± 0.099 lEq/min; UKV, 0.223 ± 0.043 lEq/min; osmolality,
950.1 ± 60.3 mOsm/kg.
bValues are means ± standard error of the mean (N = 6 to 8 mice/group).
c P ≤ 0.05 compared to the respective timed-vehicle control group.
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Fig. 1. Fractional sodium excretion and
urinary cyclic guanosine monophosphate
(cGMP) concentration following the intra-
venous administration of guanylin (GN),
uroguanylin (UGN), and heat-stable enter-
toxin (STa) in mice. Mice were treated with
10 units of peptide (GN, 64.4 lg/kg; UGN,
18.8 lg/kg; STa, 1.72 lg/kg) or vehicle as de-
scribed in Tables 1 to 3. Fractional Na+ ex-
cretion (%) is shown as a function of time
for GN, UGN, STa, and vehicle. Inset: Uri-
nary cGMP levels (expressed as fractional
cGMP excretion, FEcGMP) were assessed at
60 minutes postpeptide injection. Values are
means ± standard error of the mean (N =
6-8 mice/group per time point) and each point
represents the total fractional excretion for
that specific time point (i.e., six to eight mice
were used to determine the FENa at 20 min-
utes, six to eight were used to determine the
FENa at 40 minutes, and so on). ∗P < 0.05 com-
pared to the respective timed-vehicle control
group.
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Fig. 2. Molecular changes in kidney by intravenous uroguanylin (UGN) treatment. Differential display-polymerase chain reaction (DD-PCR) and
Northern analysis were performed using kidney RNA from mice treated (bolus 50 lL injection via tail-vein) with vehicle or UGN (18.8 lg/kg body
weight). (A and B) The DD-PCR profile from 10 arbitrary primer sets using DNase-treated kidney RNA from four separate mice, two control
vehicle-treated mice (−), and two UGN-treated mice (+). Arrows identify two specific amplified products (A, Set 4) and (B, Set 1) that were excised
from the gel, reamplified, subcloned, and sequenced. M is the size markers in kilobases (kb). (C) Representative Northern blot of kidney RNA
from mice treated with vehicle (Cont-1, Cont-2) or UGN (UGN-1, UGN-2). cDNA probes directed against the mouse ClC-K2 chloride channel
protein, Na+/K+ ATPase c -subunit, and b-actin were used during hybridization. Arrows indicate the transcripts for each product. The 18s rRNA
staining represents equal loading of the samples. (D, Relative expression, as assessed by Northern analyses, of the ClC-K2 chloride channel mRNA
and the Na+/K+ ATPase c -subunit mRNA normalized to b-actin expression (N = 3).
To further evaluate the renal effects of UGN, we exam-
ined changes in the molecular expression pattern of the
kidney induced by UGN after intravenous administration
by differential display-PCR (DD-PCR) (Fig. 2). Control
mice (N = 2) were treated with an intravenous injec-
tion of vehicle only, whereas the experimental mice (N =
2) were treated with bioactive UGN. UGN- and vehicle-
treated mice responded in a similar fashion to that shown
in Table 2. Multiple amplified products were both up- and
down-regulated compared to the control group (Fig. 2).
The arrows in Figure 2A and B are two PCR-amplified
products that were further investigated. Translation from
the sequence of the ∼1.0 kb cDNA amplification prod-
uct (Fig. 2A) corresponded to the ClC-K2 chloride chan-
nel protein and, as previously shown [12], the sequence
from the ∼1.3 kb cDNA product (Fig. 2B) translated into
the Na+/K+ ATPase c -subunit. To confirm that both of
these mRNA species were truly down-regulated in mouse
kidney 60 minutes following intravenous UGN treat-
ment, we performed Northern analysis on whole kidney
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Table 4. Summary of uroguanylin (UGN)-regulated kidney differential display clones
Clonea Estimated sizeb bp Effect of UGN treatmentc Identity/homologyd
A:2–0455 455 Up Cyclic adenosine monophosphate (cAMP -dependent
protein kinase II-b-subunit
A:3–0405 405 Up Transcription factor ATF-4
A:4–1020 1020 Up Extracellular signal-related kinase (ERK-1)
A:4–1000 1000 Down ClC-K2
B:1–1300 1300 Down Na+/K+-ATPase c -subunit
B:2–0990 990 Up RhoB
B:3–1300 1300 Down Hepatocyte nuclear factor (HNF) 4
B:5–0650 650 Up Sodium hydrogen exchanger 1
aClone is identified as panel #: primer set #; polymerase chain reaction (PCR) clone size.
bSize of PCR clone is estimated by comparison to the migration of the molecular size standards in the polyacrylamide gel.
cEffect of the PCR clone by UGN treatment was determined by DD-PCR signal comparison between vehicle and peptide treatment groups and confirmed by
semiquantitative reverse transcription (RT)-PCR (by previously described methods [39]).
dIdentity of each clone was determined by sequencing and comparison to GENEBank database.
Table 5. Comparison of guanylin (GN)-, uroguanylin (UGN)-, and heat-stable entertoxin (STa)-induced changes in renal function in wild-type
and GC-C knockout mice
Cyclic guanosine
monophosphate/
Urinary flow UNaV UKV creatinine Osmolality
Straina lL/min lEq/min lEq/min FENa % FEK % nmol/mg mOsm/kg Number
Wild-type mice
Vehicle-controlb,c 1.83 ± 0.36 0.39 ± 0.09 0.39 ± 0.10 1.88 ± 0.21 27.4 ± 4.3 11.1 ± 2.9 848.6 ± 78.3 7
Guanylin 3.75 ± 0.70d 1.48 ± 0.31d 0.99 ± 0.25d 3.51 ± 0.39d 47.0 ± 7.5d 26.5 ± 4.9d 816.3 ± 58.8 5
Uroguanylin 3.88 ± 0.42d 1.64 ± 0.40d 0.95 ± 0.30d 3.74 ± 0.44d 43.7 ± 8.0d 26.9 ± 6.9d 862.9 ± 86.5 5
STa 4.00 ± 0.55d 1.88 ± 0.38d 1.11 ± 0.33d 4.17 ± 0.55d 46.1 ± 9.2d 28.5 ± 6.3d 890.7 ± 110.6 5
GC-C(−/−) null mice
Vehicle-control 2.25 ± 0.29 0.29 ± 0.07 0.35 ± 0.09 0.91 ± 0.10 23.2 ± 3.7 14.0 ± 3.4 924.8 ± 34.0 5
Guanylin 3.38 ± 0.60d 1.07 ± 0.25d 1.08 ± 0.22d 2.81 ± 0.41d 58.3 ± 8.6d 30.9 ± 6.8d 992.0 ± 77.2 5
Uroguanylin 3.50 ± 0.51d 1.34 ± 0.39d 1.21 ± 0.38d 3.40 ± 0.52d 51.4 ± 10.0d 37.9 ± 8.2d 900.2 ± 92.1 5
STa 3.67 ± 0.49d 1.47 ± 0.50d 1.42 ± 0.41d 3.56 ± 0.59d 64.5 ± 11.3d 36.4 ± 5.6d 1002.3 ± 109.2 5
Abbreviations are: UNaV = sodium excretion; UKV = potassium excretion; FENa = fractional excretion of sodium; FEK = fractional excretion of potassium.
aWild-type mice are S129/Sv-Black Swiss hybrids; Homozygous GC-C(−/−) null mice were obtained by intercrossing heterozygotes and are thus hybrids of
129/Sv-Black Swiss
bTimed (60 minute) vehicle-control values were determined as described previously in Table 1. Vehicle or peptide (dissolved in vehicle) was administered by tail-vein
injection (50 lL bolus). The urine was collected and measured 60 minutes postinjection. Plasma and urinary sodium, potassium, osmolality, and creatinine were obtained
after each 60-minute time point from the timed vehicle-control and peptide-treated groups.
cValues are means ± standard error of the mean (N = 5–7 mice/group).
dP ≤ 0.05 compared to the respective timed-vehicle control group.
RNA from mice treated with UGN or vehicle. Shown in
Figure 2C and D, both the ClC-K2 and the Na+/K+
ATPase c -subunit transcripts are decreased upon UGN
treatment by over 75% and 60%, respectively. Additional
cDNA products were removed from the differential dis-
play gels, purified, and subjected to semiquantitative RT-
PCR, as previously reported [12, 32]. A list of products
(confirmed by PCR product sequence analysis) and their
approximate size is shown in Table 4. Further character-
ization of these potentially important cDNAs and their
impact on UGN signaling and regulation in the kidney
are currently being investigated through quantitative RT-
PCR and Northern analyses.
Renal effects of GN, UGN, and STa in GC-C(−/−)
null mice
To determine whether the effects of GN and UGN
in the kidney are mediated by its cognate receptor,
GC-C, we employed the in vivo modified renal func-
tion assay in mice deficient of GC-C (GC-C(−/−) null)
[41]. These knockout mice were originally developed
to test for the impact of GC-C–mediated physiologic
events in the intestine. However, since recent studies
have shown the agonists for this receptor exhibit re-
nal properties, we hypothesized the renal effects of
GN, UGN, and STa would be attenuated in GC-C(−/−)
null mice. Using an optimum time and concentra-
tion of the peptides in the assay (as determined in
Tables 1 to 3), GC-C(−/−) null mice responded to exoge-
nous GN, UGN, and STa in a similar fashion to normal
wild-type mice (Table 5). In fact, in both wild-type and
GC-C(−/−) null mice, GN, UGN, and STa all indepen-
dently increased urine volume and urinary sodium con-
centrations by over twofold and fourfold, respectively. In
addition, fractional sodium excretion in GC-C(−/−) null
mice was significantly increased by GN (3.1-fold), UGN
(3.7-fold), and STa (3.9-fold) when compared to vehicle
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Fig. 3. Northern blot analysis of wild-type and GC-C(−/−) null mouse RNA from colon and kidney cortex. (A) Hybridization of RNA from
wild-type (+/+) and GC-C(−/−) null (−/−) mouse colon and kidney cortex with a mouse GC-C cDNA probe (Assn ID #BC034064, IMAGE
clone 4208530) reveals the absence of the 3.8 kb GC-C transcript from the GC-C(−/−) null mouse. (B) Hybridization using the renal 400 bp
polymerase chain reaction (PCR) product from the GC-C(−/−) null mouse kidney indicates the presence of a 3.8 kb transcript containing a guanylin
(GN)/uroguanylin (UGN) binding site region in wild-type mouse colon and kidney cortex (probably GC-C), and a 2.5 kb transcript in wild-type
and GC-C(−/−) null mouse kidney cortex (GN/UGN-receptork). (C) b-actin hybridization to the same blot.
control-treated mice, which were similar to the peptide-
induced responses observed in wild-type mice. Further-
more, elevations in urinary cGMP were associated with
increased sodium excretion. In wild-type mice, the pep-
tides increased the urinary levels of cGMP by approxi-
mately 2.5-fold. In GC-C(−/−) null mice, urinary cGMP
was increased over the control-group by 2.2-fold (GN),
2.7-fold (UGN), and 2.6-fold (STa). Potassium excretion
was also significantly increased by 2.5- to 2.7-fold in wild-
type and GC-C(−/−) null mice by all three peptides. The
osmolalities in the wild-type or knockout mice did not sig-
nificantly differ between the vehicle- or peptide-treated
groups. Thus, in mice, the effect of GN, UGN, and STa are
mediated, in part, by a GC-C independent mechanism.
Northern analysis of wild-type and GC-C(−/−)
null mouse RNA
Using colon and renal cortex RNA from wild-type and
GC-C(−/−) null mice, Northern analysis was performed
using two different molecular probes directed against
the GN/UGN receptor: (1) the intracellular catalytic do-
main of wild-type mouse GC-C (Assn ID #BC034064),
and (2) a 400 bp PCR product homologous to the GC-
C ligand-binding homology domain from the GC-C(−/−)
null mouse kidney. The signal at approximately 3.8 kb
demonstrates the presence of GC-C in the colon of wild-
type mice (Fig. 3A). Also, as previously shown, this 3.8 kb
GC-C transcript is absent in colonic RNA isolated from
GC-C(−/−) null mice [41]. Similarly, the message for GC-
C is absent in kidney RNA from GC-C(−/−) null mice.
When using the same blot probed with the 400 bp PCR
GC-C–like product from GC-C(−/−) null mice, a signal
at 3.8 kb in the wild-type colon and kidney is observed
(Fig. 3B). However, an alternative, smaller signal of
∼2.5 kb is also observed in the wild-type and GC-C(−/−)
null mouse kidney. This smaller transcript is absent in
RNA isolated from colonic tissue.
DISCUSSION
Considerable evidence exists suggesting that GN and
UGN play an important role in salt and water regulation
in the kidney [12, 14, 32–34, 37, 39, 49–51]. This report
describes that exogenous GN, UGN, and their bacterial
mimic peptide STa, administered intravenously, not only
increase sodium and potassium excretion in vivo, but that
the renal effects are time- and dose-dependent. The most
significant increase in sodium and potassium excretion
was observed approximately 40 minutes following intra-
venous administration of each peptide. In addition, the
time-dependent increase in fractional sodium excretion
by these peptides was associated with a significant in-
crease in urinary cGMP and a decrease in GFR, suggest-
ing that GN, UGN, and STa elicit their effects in a renal
tubular, rather than a hemodynamic, mechanism.
Current data are consistent with the concept that GN
and UGN can affect renal function by binding to GC-C
receptors located on several nephron segments [32, 34,
37, 52–54]. However, data from this report suggests that
GN and UGN are able to elicit natriuretic and kaliuretic
effects in a GC-C–independent mechanism (Table 5).
One possible explanation for these results is that alter-
native GN/UGN/STa receptors exist in the kidney. In
wild-type mice, the physiologic effects of these peptides
may be due to a combination of both GC-C and the al-
ternative receptor(s). This concept is supported by our
preliminary molecular studies demonstrating the pres-
ence of two distinct mRNA transcripts (3.8 and 2.3 kb)
using GC-C–like molecular probes (Fig. 3). In addition,
GC-C–independent cellular and physiologic responses
to GN, UGN, and STa have been described in the kid-
ney [37, 50]. For example, a UGN-induced mechanism
was found to regulate ion conductances (and mediate
electrogenic electrolyte transport) specifically within iso-
lated collecting duct cells from GC-C−/− null mice [50].
The precedence of an alternate receptor for natriuretic
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peptides, however, is not unusual. Atrial natriuretic
peptide binds to a guanylate cyclase-coupled receptor,
guanylate cyclase-A (GC-A), and a truncated clearance
receptor (NPC-R) that is devoid of the intracellular pro-
tein kinase-like and guanylate cyclase domains[55]. NPC-
R functions to decrease the bioavailability of secreted
natriuretic peptides (ANP, BNP, CNP) in neural, renal,
and vascular tissue and/or modulate cAMP-driven sec-
ond messenger cascades [56]. In fact, agonist binding to
NPC-R in endothelial cells inhibits cAMP production via
a Gi protein-coupled signaling system. Thus, an alternate
receptor for GN and/or UGN may exist in the kidney that
also regulates renal sodium and chloride transport.
Based on the existing literature, at least two potential
confounds should be taken into consideration. First, it
has yet to be established where functional GC-C or al-
ternate GN/UGN receptors are located within specific
nephron segments. Our previous data would suggest that
primary sites of action would include the proximal con-
voluted tubule, medullary thick ascending limb, and the
cortical collecting tubules as targets for GN, UGN, and
STa[32]. Thus, further detailed segmental analysis em-
ploying in vivo micropunture and in vitro microperfusion
are necessary to identify specific nephron segments con-
taining functional GN/UGN/STa sites of action. Second,
it is quite possible that GN, UGN, and STa may act by
modulating the effects of other ligands on renal tubular
transport. For example, studies with ANP showed that
it has no effect on basal proximal tubule fluid reabsorp-
tion, but attenuates angiotensin II stimulated transport
[57]. In this regard, Santos et al [58] have made the some-
what paradoxic observation that UGN can attenuate the
ANP-induced increase in fractional sodium and potas-
sium excretion in the isolated perfused rat kidney.
Under normal physiologic conditions, GN and UGN
circulate in the bloodstream [34, 53, 54, 59–64]. The pri-
mary source of these peptides has been proposed to be the
intestine [9, 63, 65]. Two separate groups have recently
found that these peptides are secreted basolaterally as
well as from the apical/luminal surface of intestinal cells
[18, 63]. The expression and/or secretion of intestinal GN
and UGN is affected in vivo by acute salt intake, and in
vitro, by hypertonic solutions [18, 37, 39, 53, 59, 66]. In
fact, our laboratory has recently shown that rats on a low
salt diet have lower circulating levels of GN and UGN
than rats on a normal- or high-salt diet [abstract; Green-
berg RN et al, FASEB J 17:A1074, 2003]. In contrast,
plasma concentrations of UGN by Fukae et al [49], in rats
on a low- and high-salt diet did not significantly differ, al-
though the urinary excretion of UGN was significantly
higher in rats on the high-salt diet compared to those on
a low-salt diet. Furthermore, UGN mRNA expression in
the kidney, as well as urinary sodium and cGMP excre-
tion, significantly correlated with the increased urinary
UGN levels.
The response to salt intake and the natriuretic activ-
ity of these intestinal peptides has led to the hypothe-
sis that GN and UGN may participate in an enterorenal
control system. In this system, changes in dietary NaCl
intake lead to the appropriate changes in intestinal and
plasma levels of GN and UGN, which in turn, alter renal
sodium excretion. The idea of an intestinal natriuretic
factor(s) is supported by the fact that the natriuretic re-
sponse of the kidney to an increased sodium load oc-
curs faster when the load is delivered orally than when
the same load is delivered intravenously [7–9]. There are
well-established precedents for such feed-forward con-
trol systems within the gastrointestinal tract. For exam-
ple, glucose-dependent insulinotropic peptide is released
from the intestine in response to ingestion of a meal and,
in turn, stimulates the pancreatic release of insulin prior
to increases in plasma glucose concentration [67]. The in-
tent of this report was to rigorously evaluate the renal
effects of GN and UGN in a modified mouse clearance
model that lends itself to addressing questions concerning
the physiologic role of these peptides and their postulated
endocrine role in sodium regulation. Our studies suggest
a renal role for GN and UGN. Significant responses (i.e.,
increased sodium and potassium excretion) induced by
these peptides are observed within 20 minutes and are
continued until the end point of the assay (120 minutes).
It is interesting to note that UGN induces a greater frac-
tional sodium excretion than GN, which may be due to the
inherent differences in primary and secondary structure
of these peptides [9, 14, 24].
We compared the activity of GN, UGN, and STa follow-
ing a 2-hour incubation of the peptides in mouse plasma.
These stability studies were performed prior to injecting
the peptides into mice. GN, UGN, and STa appear to be
stable in plasma, with ∼95% or more of the peptide ac-
tivity being retained after incubation (data not shown).
The results for STa are similar to that observed in humans
[68]. These data suggest that all three peptides should re-
tain appropriate biologic activity in the modified mouse
clearance studies, and thus, bind to and activate renal
GN/UGN/STa receptors.
Associated with the natriuretic response induced by
UGN in mice were changes in the mRNA levels of a
series of kidney-specific transport-associated proteins.
One of the putative gene products isolated by DD-PCR
coded for the c -subunit of the Na+/K+ ATPase, which
constitutes one of the major sodium pumps in the kid-
ney. Our results suggest that intravenous UGN treat-
ment induces a down-regulation of the Na+/K+ ATPase
c -subunit mRNA and quite possibly, the protein. The
c -subunit itself is a small, type I membrane protein lo-
calized on the basolateral membranes of epithelial cells
and is expressed in the medullary thick ascending limb,
distal convoluted tubules, and the inner medullary col-
lecting duct [46]. It specifically modulates the activity of
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the Na+/K+ ATPase, which maintains the membrane po-
tential, the Na+-gradient, and the transepithelial voltage
difference that energize transcellular, Na+-coupled and
paracellular ion transport [69]. The function and regu-
lation of the c -subunit is quite complex. However, re-
ports have suggested that it is a nephron/tissue-specific
regulator of the Na+/K+ ATPase, modulating the affin-
ity of sodium, potassium, and ATP [69, 70]. Thus, down-
regulation of c -subunit mRNA could, in turn, decrease
the driving force for the reabsorption of sodium in specific
nephron segments in a long-term fashion.
Exogenous UGN administration also affected the
kidney-specific chloride channel ClC-K2. This partic-
ular chloride channel plays an important role in the
transepithelial reabsorption of chloride ions and is most
abundantly expressed along the basolateral surface of
the medullary thick ascending limb, cortical collecting
tubules, and the distal tubules [71, 72]. The physiologic
significance of ClC-K2 in the kidney has not yet been
completely elucidated. However, previous reports sug-
gest that it serves as a route for transcellular chloride
transport (i.e., an exit for chloride ions in the basolateral
plasma membrane of ClC-K2–containing nephron seg-
ments)[73]. In fact, loss-of-function mutations of ClC-K2
lead to a loss of chloride ions from the body and have been
implicated in Bartter’s syndrome [71]. Down-regulation
of this channel protein (e.g., by UGN) may, in turn, lead
to the decrease of chloride reabsorption and increase uri-
nary levels of sodium and chloride.
Clearly, it should be noted that gene expression data
does not necessarily indicate changes in protein expres-
sion. Also, UGN may cause the changes in Na+/K+
ATPase c -subunit and ClC-K2, but this observation does
not establish cause and effect. To define the role of
these proteins in GN/UGN-induced natriuresis, studies
are planned with the current model using natriuretic pep-
tides other than GN, UGN, and STa in wild-type and GC-
C(−/−) null mice. If the transcripts that encode Na+/K+
ATPase c -subunit and ClC-K2 do not change upon in-
travenous administration of nonguanylin peptides, one
would assume that GN, UGN, and STa play a direct role
in the decrease of the molecular expression of these pep-
tides, and hence, potentially influence long-term renal
function. The same experiment performed in GC-C(−/−)
null mice could also be used to determine the role of
and control for the alternate UGN receptor on Na+/K+
ATPase and ClC-K2. If these genes are not down-
regulated in GC-C(−/−) null mice upon UGN treatment,
then the argument that Na+/K+ ATPase c -subunit and/or
ClC-K2 are unrelated to changes in electrolyte excretion
is stronger. However, as shown in Tables 1 to 3 and Fig-
ure 1, natriuresis occurs in a rapid and transient fashion
(less than 90 minutes). Physiologic changes (i.e., natriure-
sis) due to modifications in gene and protein expression
have not been reported within the timeframe observed
for GN and UGN action (40 minutes). Thus, the decrease
in molecular expression Na+/K+ ATPase c -subunit or
ClC-K2 mRNA may not contribute to the rapid-onset
and transient natriuresis induced by GN and UGN. A
secondary natriuretic response in mice may occur hours
after the initial exposure of the nephron to GN and UGN.
Further experiments are currently being performed to
examine the long-term effects of GN and UGN in the
wild-type and GC-C(−/−) null mouse kidney.
Sodium excretion by the kidney needs to be pre-
cisely regulated. Even small increases in sodium intake
in the absence of compensatory changes in the rate of
tubular sodium reabsorption would rapidly lead to life-
threatening salt retention [74, 75]. Daily fluctuations in
sodium intake would necessitate, at most, a change of
only a few percent in tubular reabsorption [1, 2, 74]. GN
and UGN may provide the body with such a mechanism,
whereby ingested salt regulates the expression and secre-
tion of these peptides from intestinal cells into the circula-
tion, and in turn, affects tubular sodium reabsorption via
GN/UGN receptors lining the nephron. We describe in
this report that even low levels of these intestinal natri-
uretic peptides affect renal sodium excretion in a tran-
sient, but time-dependent fashion. Further studies are
obviously necessary to clarify and quantify the effect of al-
terations in and mechanisms of NaCl intake on GN/UGN
synthesis and secretion, and the resultant changes in re-
nal transport. Molecular studies characterizing the novel
GN/UGN receptor are also warranted and are currently
underway in our laboratory. However, taken together,
our studies suggest that GN and UGN may act on the
mouse kidney causing significant natriuresis by an alter-
nate GN/UGN/STa receptor, GC-C–independent mech-
anism via renal tubular processes. Long-term renal effects
by UGN may also affect sodium transport by inhibiting
the activity and/or down-regulating the expression of spe-
cific sodium and chloride channels, such as Na+/K+ AT-
Pase and ClC-K2.
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